Nu Skin Enterprises (NYSE:NUS)‘s stock had its “buy” rating reiterated by equities research analysts at Pivotal Research in a note issued to investors on Wednesday. They presently have a $85.00 price target on the stock. Pivotal Research’s price objective indicates a potential upside of 22.30% from the stock’s current price.
The analysts wrote, “We do expect share repurchase to accelerate and contribute meaningfully to 2019 and 2020. In 2018 diluted shares rose 2.3% compared to -2% in 2017; and -4.9% in 2016. NUS loves to shrink its share count. We think 2019 might be bigger than usual which is not in the guidance. We find the multi-year prospects for NUS shares to be excellent. Top line growth and expanding EBIT margins, accelerating share repurchases and a tax rate that may drift lower sets the stage for double-digit gains in EPS for many years. Management is excellent and improving the speed to market and technology of the business. It really is a near-perfect setup.””
Several other equities research analysts also recently commented on NUS. Zacks Investment Research downgraded shares of Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research note on Tuesday, October 23rd. Jefferies Financial Group reaffirmed a “buy” rating and issued a $92.00 target price on shares of Nu Skin Enterprises in a research note on Thursday, November 8th. Citigroup set a $88.00 target price on shares of Nu Skin Enterprises and gave the company a “buy” rating in a research note on Thursday, November 8th. Tigress Financial reaffirmed a “buy” rating on shares of Nu Skin Enterprises in a research note on Wednesday, November 21st. Finally, Bank of America reaffirmed an “underperform” rating and issued a $65.00 target price (down previously from $75.00) on shares of Nu Skin Enterprises in a research note on Thursday, December 6th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $80.50.
In other news, General Counsel D Matthew Dorny sold 1,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 2nd. The shares were sold at an average price of $60.60, for a total value of $75,750.00. Following the completion of the transaction, the general counsel now owns 32,621 shares in the company, valued at $1,976,832.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 3.00% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in NUS. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in shares of Nu Skin Enterprises by 410.1% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 427,800 shares of the company’s stock valued at $35,259,000 after buying an additional 343,935 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Nu Skin Enterprises by 524.5% in the third quarter. Assenagon Asset Management S.A. now owns 295,551 shares of the company’s stock valued at $24,359,000 after buying an additional 248,222 shares during the period. BlackRock Inc. boosted its holdings in shares of Nu Skin Enterprises by 3.4% in the fourth quarter. BlackRock Inc. now owns 6,273,298 shares of the company’s stock valued at $384,741,000 after buying an additional 205,481 shares during the period. SG Capital Management LLC acquired a new position in shares of Nu Skin Enterprises in the fourth quarter valued at approximately $11,323,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Nu Skin Enterprises in the third quarter valued at approximately $12,882,000. Institutional investors own 76.69% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Featured Story: How Do Investors Open a Backdoor Roth IRA?
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.